Original article
Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: Clinical and epidemiologic observations

https://doi.org/10.1016/S0022-3476(05)81600-2Get rights and content

Purpose: To describe an outbreak ofEscherichia coli O175:H7 infection resulting in a high rate of progression to hemolytic-uremic syndrome, and to attempt to identify predictors of and risk factors for progression.

Design: Case-control study among employees and comparison of daily clinical features in two groups: infected residents with subsequent development of HUS and those who had no complications.

Setting: Two institutions for retarded persons in Utah.

Patients: Twenty residents with E. coll O157:H7 infection (13 culture confirmed, 2 probable, and 5 possible); HUS developed in 8, and 4 died. Thirty-one infected employees (3 with culture-confirmed, 6 with probable, and 22 with possible infection).

Measurements and main results: In a case-control study among employees, infection was independently assoclated with eating ground beef from a single lot prepared at several barbecues and with close contact with a resident who had diarrhea. Five of eight residents in whom HUS developed had received trimethoprim-sulfamethoxazole, compared with none of seven who had no subsequent complications (p=0.026); this finding may reflect antimicrobial treatment of patients with more severe illness. Compared with infected residents without complications, persons with HUS were younger (median age 13 vs 27 years, p=0.043) and, by the third day of illness, had higher leukocyte counts (median 23.7×109/L vs 9.1×109/L, p=0.018) and temperature (median 38.5°C vs 37.0° C, p=0.016). Leukocytosis peaked on day 4, more than 24 hours before signs of HUS appeared.

Conclusions: Food-borne outbreaks of E. coli O157:H7 in insitutions may have devastating effects. Leukocytosis and fever may precede and predict HUS in patients with E. coli O157:H7 infection.

References (35)

  • DrummondK

    Hemolytic uremic syndrome—then and now

    N Engl J Med

    (1985)
  • KarmaliM et al.

    The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing strains of Escherichia coli

    J Infect Dis

    (1985)
  • GransdenW et al.

    Further evidence associating hemolytic uremic syndrome with infection by verotoxin-producing Escherichia coli O157:H7

    J Infect Dis

    (1986)
  • NeillM et al.

    Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest

    Pediatrics

    (1987)
  • RoweB et al.

    Haemorrhagic colitis and haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli (VTEC) in England and Wales

  • RatnamS et al.

    Sporadic occurrence of hemorrhagic colitis associated with Escherichia coli O157:H7 in Newfoundland

    Can Med Assoc J

    (1986)
  • PaiC et al.

    Sporadic cases of hemorrhagic colitis associated with Escherichia coli O157:H7

    Ann Intern Med

    (1984)
  • Cited by (239)

    • Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview

      2019, Journal of Infection
      Citation Excerpt :

      In vivo studies have demonstrated that, while some benefit may exist from the early administration of TMP/SMX, it is soon lost, with HUS ensuing if the drug is administered three days after the inoculation of bacteria.30 Nevertheless, quite a few clinical studies concerning TMP/SMX are available, the majority of which report that its use increases the incidence of HUS8,49,55,57 and even more so if administered during the first 72 h after the onset of symptoms.57 Only one study reported that the administration of TMP/SMX for more than 24 h in patients with STEC O157:H7 infection prevented its progression to HUS,59 while two others concluded that administration of sulfonamides38 or TMP/SMX33 had no effect in the occurrence of HUS.

    • Effect of lactoferrin on release and bioactivity of Shiga toxins from different Escherichia coli O157:H7 strains

      2017, Veterinary Microbiology
      Citation Excerpt :

      Some studies associate the administration of antibiotics with higher risk for HUS as well as with longer duration of diarrhoea and/or bloody diarrhoea. Patients treated with trimethoprim/sulphamethoxazole tended to have longer duration of diarrhoea and bloody diarrhoea and were more likely to develop HUS than patients who did not receive an antibiotic, although this negative effect was not seen for ampicillin treatment (Pavia et al., 1990; Ostroff et al., 1989). Antibiotics affect the release of Stx, but do not cause degradation of the toxin.

    • A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection

      2015, International Journal of Antimicrobial Agents
      Citation Excerpt :

      They then cause direct damage to endothelial cells as well as indirect damage by the activation of neutrophils [15]. Pavia et al. [11] found that a patient's illness from E. coli O157 peaked on the fourth day. From these observations, it is suggested that in order to prevent the development of HUS in patients with E. coli O157, patients need to be treated during the early period of the illness.

    View all citing articles on Scopus
    View full text